Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 10/20 | 0.53 |
| ▸ | EBP | Q15125 | 1/20 | 0.51 |
| ▸ | MCHR2 | Q969V1 | 7/20 | 0.50 |
| ▸ | DRD2 | P14416 | 2/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2758090 | 0.93 | MCHR2 (0.52) | SIGMAR1EBPMCHR2DRD2SLC6A4 | |
| SCHEMBL2758170 | 0.89 | MCHR2 (0.47) | SIGMAR1EBPMCHR2DRD2SLC6A4 | |
| SCHEMBL2758183 | 0.87 | MCHR2 (0.49) | SIGMAR1EBPMCHR2DRD2SLC6A4 | |
| SCHEMBL2758016 | 0.87 | MCHR2 (0.47) | SIGMAR1MCHR2DRD2SLC6A4KCNH2 | |
| SCHEMBL12999742 | 0.86 | MCHR2 (0.46) | SIGMAR1MCHR2DRD2SLC6A4KCNH2 | |
| SCHEMBL241428 | 0.85 | MCHR2 (0.48) | MCHR2DRD2SLC6A4KCNH2 | |
| SCHEMBL241429 | 0.85 | MCHR2 (0.48) | MCHR2DRD2SLC6A4KCNH2 | |
| SCHEMBL2758063 | 0.85 | MCHR2 (0.48) | MCHR2DRD2SLC6A4KCNH2 | |
| SCHEMBL2758157 | 0.85 | MCHR2 (0.48) | MCHR2DRD2SLC6A4KCNH2 | |
| SCHEMBL12293251 | 0.85 | MCHR2 (0.60) | SIGMAR1EBPMCHR2DRD2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8304423-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2012-11-06 | — | — | US | disclosed |
| US-8304423-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2012-11-06 | — | — | US | disclosed |
| US-20120196857-A9 | Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-02 | — | — | US | disclosed |
| US-20120196857-A9 | Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-02 | — | — | US | disclosed |
| US-20120004226-A1 | Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-05 | — | — | US | disclosed |
| US-20120004226-A1 | Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-05 | — | — | US | disclosed |
| US-8003660-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-08-23 | — | — | US | disclosed |
| US-8003660-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-08-23 | — | — | US | disclosed |
| US-20070213315-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2007-09-13 | — | — | US | disclosed |
| US-20070213315-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213315-A1 | Modulators of muscarinic receptors | CHRM3, CHRM5, CHRM2 | SIGMAR1 237/4885EBP 2877/4885MCHR2 159/4885 |
| US-20120004226-A1 | Modulators of Muscarinic Receptors | CHRM3, CHRM5, CHRM2 | SIGMAR1 237/4885EBP 2877/4885MCHR2 159/4885 |
| US-20120196857-A9 | Modulators of Muscarinic Receptors | CHRM3, CHRM5, CHRM2 | SIGMAR1 237/4885EBP 2877/4885MCHR2 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.